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Abstract
Esophageal squamous cancer (ESC) is one of the most aggressive tumors of the gastrointestinal tract. A combination of
chemotherapy and radiation therapy (CRT) has improved the clinical outcome, but themolecular background determining
the effectiveness of therapy remains unknown. NRF2 is a master transcriptional regulator of stress adaptation, and gain-
of-function mutation of NRF2 in cancer confers resistance to stressors including anticancer therapy. Direct resequencing
analysis revealed thatNrf2 gain-of-function mutation occurred recurrently (18/82, 22%) in advanced ESC tumors and ESC
cell lines (3/10). The presence of Nrf2mutation was associated with tumor recurrence and poor prognosis. Short hairpin
RNA–mediated down-regulation of NRF2 in ESC cells that harbor only mutatedNrf2 allele revealed that the mutant NRF2
conferred increased cell proliferation, attachment-independent survival, and resistance to 5-fluorouracil and γ-irradiation.
Based on theNrf2mutation status, gene expression signatures associatedwithNRF2mutation were extracted from ESC
cell lines, and their potential utility for monitoring and prognosis was examined in a cohort of 33 pre-CRT cases of ESC.
Themolecular signatures ofNRF2mutation were significantly predictive and prognostic for CRT response. In conclusion,
recurrent NRF2 mutation confers malignant potential and resistance to therapy in advanced ESC, resulting in a poorer
outcome. Molecular signatures ofNRF2mutation can be applied as predictive markers of response to CRT, and efficient
inhibition of aberrant NRF2 activation could be a promising approach in combination with CRT.
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Introduction
Esophageal cancer (EC) is the sixth most common cause of cancer
death worldwide [1]. The 5-year survival rate of patients with EC is
reportedly less than 20%, making it one of the most aggressive tumors
of the gastrointestinal tract [2]. Epidemiologically, alcohol consump-
tion, cigarette smoking, and a preference for hot beverages, as well as
the presence of Barrett esophagus resulting from gastroesophageal re-
flux, have been reported as risk factors for EC [3,4], and more than
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460,000 patients develop this cancer annually worldwide [1]. Esopha-
geal squamous cancer (ESC) is the predominant type of EC, being
prevalent in Africa and Eastern Asia including Japan [5].
Currently, only surgical resection can be regarded as a curative
therapy for ESC, and adjuvant or neoadjuvant combination of che-
motherapy with radiation therapy (CRT) has recently improved the
clinical outcome [6–8]. However, responsiveness to CRT varies
among patients, and the molecular backgrounds that determine ther-
apeutic effectiveness remain largely unknown [6]. Therefore, the dis-
covery of molecular markers for precise prediction of responsiveness
to therapy is eagerly anticipated. It is also necessary to construct ef-
fective personalized therapeutic modalities based on the molecular
characterization of ESC.
Oxidative stress has been shown to play important roles in the car-
cinogenesis and progression of many cancers including ESC [9–11]. In
response to intrinsic (e.g., reactive oxygen species generated in mito-
chondria) and extrinsic (e.g., radiation) oxidative stresses, NEF2L2
(nuclear erythroid factor 2-like 2, or NRF2) functions as a master tran-
scriptional regulator of cytoprotective genes [12]. Under physiological
conditions, KEAP1, an E3 ubiquitin ligase, directly interacts with two
amino-terminal motifs (DLG and ETGE) of NRF2 and negatively reg-
ulates its expression level through the proteasome [13]. Recently, it has
been revealed that aberrant activation of the NRF2 pathway occurs fre-
quently in cancer. We and other groups have reported that the Keap1
gene is inactivated in a wide range of cancers [14–18]. Moreover, we
have discovered that the Nrf2 gene is a bona fide oncogene in lung and
head/neck cancers [19]. In the present study, we discovered that NRF2
mutation also occurs frequently in ESC and examined its clinical sig-
nificance especially from the viewpoint of responsiveness to CRT.
Materials and Methods
Clinical Samples and DNA Extraction
All surgical specimens were obtained from patients who had been
diagnosed and had undergone surgery at the National Cancer Center
Hospital, Tokyo, Japan (pathologic diagnoses are presented in
Table W1). Tumor cells and corresponding lymphocytes or non-
cancerous tissues were dissected under a microscope from methanol-
fixed or formalin-fixed (in situ carcinoma) paraffin-embedded tissues,
and the DNA was extracted. High-molecular-weight DNA was also
extracted from cell lines using DNAeasy (QIAGEN, Hamburg,
Germany). Clinical data, including therapeutic response and prognosis,
were collected from the medical charts. The protocol for analysis of the
clinical samples was approved by the institutional review board of the
National Cancer Center.
Polymerase Chain Reaction and Sequence Analysis
We amplified all exons of the Nrf2 gene by polymerase chain reaction
(PCR) using High-Fidelity Taq polymerase (Roche Diagnostic, Basel,
Switzerland), as described [19]. The PCR products were then purified
(QIAquick PCR Purification Kit; QIAGEN) and analyzed by sequenc-
ing (Big Dye Sequencing Kit; Applied Biosystems, Carlsbad, CA).
Biologic and Biochemical Experiments
Ten ESC cell lines (KYSE-30, -50, -70, -110, -140, -150, -170,
-180, -220, and -270) were obtained from the Japanese Collection of
Research Bioresources (http://cellbank.nibio.go.jp) and maintained in
Dulbecco modified Eagle medium supplemented with 10% fetal
bovine serum. Construction of the retroviral expression vector of
short hairpin RNA (shRNA) was carried out as described previously
[20]. The shRNA-targeted sequences were as follows: NRF2–
shRNA-1, ACTTGCTCAATGTCCTGTTGC; NRF2–shRNA-2,
AGTTGAGCTTCATTGAACTGC. The control vector contains
nontargeting shRNA sequence. The entry vectors were recombined
with pDEST-CL-SI-MSCVpuro by LR reactions (Invitrogen, Carlsbad,
CA), in accordance with the manufacturer’s instructions. After infection
(multiplicity of infection > 1), cells were selected and maintained in the
presence of 1 μg/ml puromycin. NRF2 small interfering RNA (siRNA)
was previously described [19]. NRF2-dependent luciferase activity was
measured as described [15]. Cell proliferation was measured using the
96-well plate format by bromodeoxyuridine incorporation (Cell Pro-
liferation ELISA; Roche Diagnostic). For attachment-free culture, 1 ×
106 cells were seeded in ultra low-attachment dish (Ultra Low Cluster
Plate, Corning, NY). 5-Fluorouracil (5-FU) was purchased fromWAKO
(Tokyo). Irradiation of cells was performed using the 60Co source in the
Gammacell 220 Research Irradiator (MDS Nordion, Ontario, Canada).
The intracellular level of reduced glutathione was measured by GSH-Glo
Glutathione Assay (Promega, Madison, WI). Protein extraction and
immunoblot analysis were performed as described previously [15]. Anti-
bodies used in this study are listed in Table W1.
Gene Expression Profiling and Quantitative Reverse
Transcription–PCR
Ten micrograms of total RNA from ESC cell lines was reverse-
transcribed by MMLV-RT, and a Cy3-labeled complementary RNA
probe was synthesized using T7 RNA polymerase and hybridized with
a microarray covering the whole human genome (Whole Human
Genome Oligo Microarray, G4112F; Agilent Technologies, Santa
Clara, CA). After washing, the microarray was scanned by the DNA
microarray scanner (Agilent Technologies). Data were analyzed using
GeneSpring software (Agilent Technologies). Quantitative reverse tran-
scription (RT)–PCR was performed in triplicate and evaluated using
universal probes for each amplicon and the LightCycler system
(Roche). Primers designed by ProbeFinder (Version 2.45; Roche)
and used in this study are shown in Table W2. The relative expression
of each gene was determined by comparison with that of glyceraldehyde-
3-phosphate dehydrogenase (GADPH).
Statistics
Statistical analysis of clinicopathologic data was performed using the
StatView software package. Gene Set Enrichment Analysis (GSEA) was
performed as follows. First, a gene list sorted in descending order based
on fold change differences in expression between NRF2-mutated and
wild-type ESC cell lines was calculated. Second, preranked GSEA was
applied for the gene list to the C2 curated gene sets (MSigDB ver. 2.5)
with default parameters (http://www.broadinstitute.org/gsea/index.
jsp). Finally, significant gene sets were extracted if the false discovery
rate (FDR) was less than 25%. To evaluate the predictive power of gene
expression signatures for CRT and prognosis, biopsy samples with clin-
ical information were classified into two groups by K-means clustering
(R cluster package) using gene expression signatures for each significant
gene set of GSEA, and then survival analysis was applied to the classi-
fied samples. The survival analysis was performed using the Kaplan-
Meier method, and log-rank test was used to evaluate disease-free
survival. To determine whether the NRF2 target genes based on ChIP-
seq (chromatin immunoprecipitation sequence) [21] were enriched in
any gene sets, we calculated the P values using the hypergeometric dis-
tribution for each the C2 curated gene sets and estimated the FDR.
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Because the NRF2 ChIP-seq data were measured using a mouse cell
line, we then converted the mouse genes to human genes using NCBI
HomoloGene to apply them as a human gene set C2. We used a 10%
FDR cutoff for this enrichment study.
Results
NRF2 Mutation in ESC
To evaluate the prevalence of NRF2 mutation in human cancer,
we attempted resequencing analysis of the entire coding region of the
NRF2 gene in a cohort (320 samples in total) of epithelial and none-
pithelial tumors (pathologic diagnoses are shown in Table W2). We
detected six nonsynonymous somatic mutations in the ECs (6/32,
18.8%) and one nonsynonymous somatic mutation in cervical cancer
(1/18, 5.6%) and malignant melanoma (1/22, 4.5%), respectively
(Figure 1A and Table 1). We additionally analyzed 50 cases of ESC
and identified a total of 18 somatic mutations (18/82, 22%; Table 1).
These mutations exclusively affected amino acid residues within and
surrounding the KEAP1 binding motif, as reported previously in lung
cancers [19]. We then analyzed 10 ESC cell lines and found three
NRF2-mutated ones (3/10; Figure 1B and Table 1), of which two
(KYSE70 and KYSE180) harbored homozygous mutations. NRF2-
mutated KYSE70 and KYSE110 cells were established from poorly
differentiated ESC. No KEAP1 mutation was detected in ESC cases
(data not shown). We additionally analyzed 36 cases of intraepithelial
(in situ) ESC and detected no NRF2mutation (0/36), suggesting that
NRF2mutation occurs predominantly at the advanced stage of esoph-
ageal carcinogenesis.
Association of NRF2 Mutation with Tumor Recurrence and
Poor Prognosis of ESC
To further determine the clinical significance of NRF2 gene muta-
tion in EC, we analyzed the association betweenNRF2mutation status
and clinicopathologic factors. The presence ofNRF2mutation was cor-
related with tumor recurrence (P = .046) and tended to be associated
with lymph node metastasis (P = .072). Patients with NRF2-mutated
tumors showed poorer survival (P = .005; Table 2 and Figure 1C ).
Clinical stage (P = .038) and lymph node metastasis (P = .039) were
associated with the disease-free survival of the patient (Table 2).
Figure 1. NRF2 mutation in EC. (A) Somatic NRF2 mutations are clustered in the KEAP1 binding domain. Schematic presentation of
NRF2 protein indicates the location of Neh1∼6 (Nrf2-ech homology) domains and functional annotations. Somatic mutations identified
in this study (blue) affected amino acids in the DLG or ETGE motifs. (B) Sequence chromatography of NRF2 mutations in ESC cell lines
with corresponding normal sequences in the bottom panel. KYSE70 and KYSE180 cells harbor homozygous mutations. (C) Kaplan-Meier
plot showing overall survival of ESC patients segregated according to NRF2 mutation status.
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Mutant NRF2 Has a Gain-of-Function Activity and Regulates
Proliferation and Attachment-Independent Cell Survival
in ESC Cells
We compared the transcriptional activities of ESC-associated NRF2
mutants (W24C and D77V) to that of wild NRF2 and determined that
mutant NRF2 has a gain-of-function activity, which is partly resistant
to KEAP1-mediated inhibition (Figure 2A). There was no significant
difference in transcriptional activity between homozygous (KYSE30)
and heterozygous (KYSE110) mutant cells (Figure W1).
The previously mentioned analysis of clinical samples suggested
that NRF2 mutation plays a role in metastasis and tumor progression
of ESC. Exploiting our discovery of ESC cell lines with homozygous
NRF2 mutation, we established KYSE70 cells stably expressing
shRNAs against NRF2 to examine the biologic features solely regu-
lated by mutant NRF2. We tested two different lentiviruses contain-
ing NRF2-targeted shRNA (shRNA-1 and -2) along with a control
virus. Immunoblot analysis revealed that NRF2–shRNA-2 robustly
(11.4% of control) reduced the expression of endogenous mutant
NRF2 protein compared with the NRF2–shRNA-1 clone (71.2%
of control) (Figure 2C ). Similarly, NRF2-dependent transcriptional
activity markedly decreased (8.9% of control) in shRNA-2 clone
(Figure 2D).
Table 1. NRF2 Mutation in Human Cancers.
Sex Tumor Type Nucleotide Substitution Amino Acid Change Zygosity
M Esophageal cancer (SCC) c. 70T>C p. W24K Heterozygous
F Esophageal cancer (SCC) c. 72G>C p. W24C Heterozygous
M Esophageal cancer (SCC) c. 76C>G p. Q26E Heterozygous
M Esophageal cancer (SCC) c. 66A>G p. D29G Heterozygous
M Esophageal cancer (SCC) c. 66A>G p. D29G Allelic imbalance (mut > wt)
M Esophageal cancer (SCC) c. 88C>T p. L30F Heterozygous
M Esophageal cancer (SCC) c. 92G>C p. G31A Heterozygous
M Esophageal cancer (SCC) c. 225A>C p. Q75H Heterozygous
M Esophageal cancer (SCC) c. 230A>T p. D77V Heterozygous
M Esophageal cancer (SCC) c. 230A>G p. D77G Heterozygous
M Esophageal cancer (SCC) c. 232G>A p. E78K Heterozygous
M Esophageal cancer (SCC) c. 235G>A p. E79K Heterozygous
M Esophageal cancer (SCC) c. 235G>A p. E79K Heterozygous
M Esophageal cancer (SCC) c. 235G>A p. E79K Heterozygous
M Esophageal cancer (SCC) c. 235G>A p. E79K Heterozygous
M Esophageal cancer (SCC) c. 239C>A p. T80K Heterozygous
F Esophageal cancer (SCC) c. 238A>C p. T80P Heterozygous
F Esophageal cancer (SCC) c. 242G>A p. G81D Heterozygous
M Malignant melanoma c. 88C>T p. L30F Heterozygous
F Cervical cancer (SCC) c. 235G>C p. E79Q Heterozygous
M KYSE70: Esophageal cancer (SCC) c. 72G>T p. W24C Homozygous
M KYSE110: Esophageal cancer (SCC) c. 246A>T p. E82D Heterozygous
M KYSE180: Esophageal cancer (SCC) c. 230A>T p. D77V Homozygous
Table 2. Associations among NRF2 Mutation Status, Clinicopathologic Factors, and Prognosis.
Clinicopathologic Factor No. Patients NRF2 Mutation, P Overall Survival, P Disease-free Survival, P
Sex Male 69 .914 .119 .656
Female 13
NRF2 mutation + 18 na* .005 .288
− 64
Smoking + 64 .302 .572 .557
− 18
Alcohol intake + 71 .268 .366 .143
− 11
Stage I-II 25 .709 .895 .038
III-IV 57
Invasion depth >a1 66 .186 .453 .565
<mp 16
Lymph node metastasis + 65 .072 .285 .039
− 17
Histologic differentiation Well 11 .134 .7 .074
Mod 33
Poor 38
Lymphatic infiltration + 60 .48 .746 .336
− 22
Venous involvement + 54 .631 .215 .124
− 28
Intramucosal metastasis + 10 .873 .376 .654
− 72
Tumor recurrence + 47 .046 .587 .775
− 35
“+” indicates positive; “−,” negative; >a1, invade beyond muscularis propria; <mp invade within muscularis propria; well, well differentiated; mod, moderately differentiated; poor, poorly differentiated.
*Not applicable.
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Both shRNAs reduced cell proliferation in KYSE70 cells
(Figures 2E and W2). We then measured attachment-independent
cell survival in liquid culture, which mimics the antiapoptotic activity
of floating cancer cells in tumor metastasis or recurrence. As shown
in Figure 2C , only shRNA-2 clones exhibited more apoptosis in cul-
ture conditions where adhesion to a substrate was inhibited.
Down-regulation of Mutant NRF2 Increases the Sensitivity
of ESC Cells to 5-FU
Previous studies have shown that activation of NRF2 in lung and
gallbladder cancers confers resistance to chemotherapeutic drugs
[14,15]. To determine whether NRF2 activation has any association
with drug resistance in ESC cells, we examined the sensitivity to 5-FU,
a commonly used chemotherapeutic reagent for ESC, in ESC cells. We
found that NRF2-mutated cells were relatively resistant to 5-FU treat-
ment compared with an NRF2 wild-type cell (Figure W3A) and that
NRF2–downregulated KYSE70 cells (both shRNA-1 and shRNA-2
clones) showed increased sensitivity to 5-FU (the IC50 of each clone
was 125.3, 81.3, and 13.1 μM respectively; Figure 3A). We also
reduced the expression of NRF2 in other NRF2-mutated ESC cells
using NRF2 siRNA and tested their sensitivity to 5-FU. This yielded
results similar to that for KYSE70 cell (Figure 3B).
Robust Down-regulation of Mutant NRF2 Is Required
for Enhancing Radiation Sensitivity in ESC Cells
Radiation therapy induces oxidative stress by producing reactive
oxygen species in cancer cells. Thus, it is very likely that NRF2
mutation is associated with radiosensitivity. To determine whether
mutant NRF2 has a role in acquisition of resistance to irradiation,
we exposed control and NRF2 shRNA-infected KYSE70 cells to
γ-irradiation (2 Gy) and examined their clonogenic activities (basal
colony formation activity of ESC cells is shown in Figure W3B),
which reflect the degree of irradiation-induced cellular damage. As
shown in Figure 3C , NRF2-downregulated cells (both shRNA-1
and shRNA-2 clones) were more sensitive to irradiation than control
clone. However, when the relative number of colonies was compared
among three clones, only the shRNA-2 clone showed a significant
reduction (P = .0002). This suggests that moderate (∼70%) NRF2
Figure 2. Down-regulation of gain-of-function NRF2 mutant in KYSE70 cells by shRNA. (A) Transcriptional activities of wild-type and ESC-
associated mutant NRF2 were measures in the absence or presence of the Keap1 gene. (B) Down-regulation of NRF2 protein in KYSE70
cells treated with NRF2-targeting shRNAs. Left, Immunoblot analysis of NRF2 protein in the nuclear fraction of KYSE70 cells infected
with GFP shRNA (cont) or two different NRF2–shRNAs (sh-1 and sh-2). HEK293 cells lack NRF2 accumulation and were loaded as a
negative control. Lamin B1 was used as a loading control. Right, Relative NRF2 expression in each clone was presented. (C) NRF2-
dependent transcriptional activities of KYSE clones and HEK293. (D) Cell proliferation plot of KYSE70 clones infected with control or
NRF2–shRNAs (shRNA-1 and shRNA-2). Data are mean ± SD of three independent experiments. *P < .05, **P < .01. (E) KYSE70 clones
were cultured on an ultra low-attachment plate for 72 hours, and whole proteins were then extracted. Expression of cleaved PARP was
examined by immunoblot analysis. β-Actin was used as a loading control. Relative PARP1 expression compared with the control shRNA
was shown below. Molecular marker is indicated on the right (kDa).
868 NRF2 Mutation and Chemoradiation Therapy in ESC Shibata et al. Neoplasia Vol. 13, No. 9, 2011
down-regulation affected the colony formation activity but that a more
complete reduction (∼10%) of mutant NRF2 would be required to
enhance radiation sensitivity.
It has been reported that the intracellular glutathione level is cor-
related with sensitivity to radiation [22,23]. To determine whether
mutant NRF2 has any role in regulating the level of glutathione in
irradiated ESC cells, we measured the expression of major enzymes
(glutamate-cysteine ligase, catalytic subunit [GCLC] and glutathione
reductase [GSR]), which regulate glutathione synthesis and modifica-
tion and are direct targets of NRF2 [21,24], in NRF2-downregulated
KYSE70 cells exposed to various doses of irradiation. Quantitative
RT-PCR analysis revealed that down-regulation of mutant NRF2
(shRNA-2 clone) was significantly reduced not only for the induc-
ible expressions of GCLC and GSR but also for their basal level
(Figure 3D). Interestingly, this reduction was not obvious in the
shRNA-1 clone, which is consistent with the radiation sensitivity ex-
periment previously mentioned and suggests that robust NRF2 down-
regulation would be required for decreasing glutathione-regulatory
enzymes (Figure 3D). Consistently, the basal level and radiation-induced
increase of reduced glutathione were diminished only in the shRNA-2
clone (Figure W4).
Molecular Signatures Associated with NRF2 Mutation Are
Prognostic Factors for ESC and Predictive of Response to CRT
These in vitro data strongly suggested that NRF2 activation by
genetic alteration could be associated with the clinical response to
CRT. However, the previously mentioned ESC cohort, whose NRF2
mutation status was determined, contained only eight cases that had
received postoperative CRT. Despite the difficulty in obtaining molec-
ular data from minute biopsy samples of tumors before treatment, we
Figure 3.Mutant NRF2 confers resistance to chemotherapeutic reagent and radiation. (A) KYSE70 clones infected with control shRNA or
NRF2–shRNAs were treated with various concentrations of 5-FU. (B) KYSE180 and KYSE110 cells were treated with control or NRF2
siRNA and various concentrations of 5-FU, as in A. Data represent cell viability after 48 hours relative to vehicle (DMSO)-treated control.
Data are mean ± SD of three independent experiments; statistical difference to control siRNA or shRNA, **P< .01, ***P< .001. (C) Left,
A representative plate showing colony formation by each clone with control (0 Gy) and 2-Gy irradiation. Top right, Number of KYSE70
clones infected with control shRNA and NRF2–shRNAs that formed colonies after control (0 Gy) and 2-Gy irradiation. Data are mean ± SD
of eight independent plates. Bottom right, The relative number of colonies after 2-Gy irradiation compared with the control (0 Gy). Note
that the difference between control shRNA and shRNA-1 clones was not significant (n.s.). (D) KYSE70 clones were irradiated with dif-
ferent doses, and the expression of GCLC and GSR mRNAs was then examined. Data are mean ± SD of three independent experiments,
**P < .01. ***P < .001.
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previously collected the gene expression profiles of 33 pre-CRT samples
of ESC for which the same therapeutic protocol had been used and for
which the therapeutic response had been clinically evaluated [25].
Therefore, using this data set, we attempted to analyze whether the
gene expression signatures associated with NRF2 mutation could be
predictive markers of response to CRT in ESC.
For this purpose, we first obtained the genome-wide gene expres-
sion data for five ESC cell lines and extracted the NRF2-mutated
ESC signature based on the NRF2 mutation status (Figure 4A).
Using GSEA, we obtained a panel of molecular pathway signatures
that were significantly associated with NRF2 mutation status (rep-
resentative pathways are shown in Figure 4B). The expressions of
703 gene sets were increased, and those of 14 gene sets were de-
creased in NRF2-mutated ESC cell lines (a complete list is shown
in Table W3). We then tested whether changes in the expression
of any of these signatures were associated with the clinical response
to CRT and overall survival after treatment. We found that the in-
creased expression of 15 gene sets was significantly (P < .05) associ-
ated with both poor response to CRT and a poor patient outcome
after CRT (Table 3; representative Kaplan-Meier plots are shown in
Figure 4C ). All of the potentially predictive molecular signatures
were increased in NRF2-mutated ESC cell lines and included path-
ways related to the oxidative stress response (n = 4), immune/cytokine
response (n = 4), and hematopoietic disorder (n = 3) (Table 3). We
further elucidated that direct NRF2 target genes confirmed by a com-
bination of ChIP-seq and microarray analysis [21] were significantly
Figure 4. Pathway signatures of mutant NRF2 are associated with ESC patients’ survival after CRT. (A) Two-dimensional hierarchal clus-
tering of KYSE cells by genome-wide gene expression. NRF2 mutation status is shown at the bottom. GSEA extracted characteristic
gene sets enriched in NRF2-mutated or wild-type ESC cells, and their prognostic significance was evaluated based on gene expression
data for biopsies from pre-CRT cases. (B) Representative panels showing results of GSEA of genes enriched in NRF2-mutated ESC cell
lines. (C) Kaplan-Meier plot showing overall survival of ESC patients after CRT segregated according to the NRF2 mutant signature.
Table 3. Mutant NRF2 Signatures Associated with CRT Response.
Molecular Pathways Prognosis, P Clinical Response, P NRF2 Target Enrichment, P No. NRF2 Target Genes Functional Annotation
ET743PT650_COLONCA_DN .000103 .00404 .000917 7 Anticancer drug
GLYCOSPHINGOLIPID_METABOLISM .000744 .00519 .585 1 Glycolipid metabolism
UVB_NHEK3_C7 .000813 .0235 .00279 7 Oxidative stress response
HG_PROGERIA_DN .00132 .0109 .6 1 Aging
TAKEDA_NUP8_HOXA9_16D_UP .00306 .0186 .318 8 Hematopoietic disorder
CARIES_PULP_HIGH_UP .00466 .0186 .865 2 Immune/cytokine response
ABRAHAM_AL_VS_MM_UP .0083 .00688 .254 2 Hematopoietic disorder
ABRAHAM_MM_VS_AL_DN .0083 .00688 .24 2 Hematopoietic disorder
IFN_GAMMA_UP .00847 .045 .165 3 Immune/cytokine response
AS3_FIBRO_C4 .00865 .0235 1 0 Oxidative stress response
TSADAC_RKOSILENT_UP .0115 .045 .52 1 Methylated in colon cancer
BRCA1KO_MEF_DN .0144 .0174 .0267 7 Oxidative stress response
UVB_SCC_DN .016 .0235 .899 2 Oxidative stress response
CMV_HCMV_TIMECOURSE_24HRS_DN .0196 .045 .0169 5 Immune/cytokine response
SANA_TNFA_ENDOTHELIAL_UP .0286 .00669 .587 3 Immune/cytokine response
870 NRF2 Mutation and Chemoradiation Therapy in ESC Shibata et al. Neoplasia Vol. 13, No. 9, 2011
enriched in part of these pathways (Table 2; enriched genes are listed
in Table 4).
Discussion
NRF2 Mutation in ESC
In the present study, we conducted mutation screening of the
Nrf2 gene in a wide range of tumor types including sarcoma and
found that NRF2 mutation is specifically frequent in EC and rarely
occurs in cervical cancer and melanoma. These ESC-associated muta-
tions harbor gain-of-function activity. Because Keap1 recognizes two
distinct regions of NRF2, single amino acid change may not com-
pletely inhibit Keap1-mediated degradation or sequestration [19]. Re-
cently, Kim et al. [26] performed a mutation screening of hot spots in
the Nrf2 gene in more than 1000 tumors and reported that NRF2
mutation is recurrent in tumors of the lung, skin, esophagus, and
larynx, which is concordant with our previous and current observa-
tions. We previously reported that NRF2 mutation was more com-
mon in smoking-associated lung cancer [19]; however, we failed to
demonstrate any significant association between the presence of
NRF2 mutation and smoking history (P = .302) in ESC, probably
because most of the affected patients in our cohort (64/82, 78%) were
smokers. Also, NRF2 mutation status was not associated with the
habitual alcohol intake (P = .268). Previous genetic analyses have
shown that polymorphisms of the GSTP1 and NQO1 genes, both of
which are known direct targets of NRF2, are associated with suscep-
tibility to ESC in Asian and white populations [27–29]. It would be
interesting to examine the frequency of NRF2 mutation in other ESC
cohorts with different genetic, epidemiological, or ethnic backgrounds.
Because Keap1-deleted mice show hyperkeratosis in the forestomach
[30], which is analogous to the esophagus, NRF2 activation could
affect differentiation process of esophageal epithelium, which might
be associated with malignant features of ESC. Our analysis of a cohort
of ESC cases has further revealed the clinical significance of NRF2
mutation. Our mutation analysis revealed that NRF2 mutation was
only detected in the late stage ESC. The presence of NRF2 mutation
was associated with tumor recurrence and was shown to be a significant
prognostic factor. A recent study aimed at identifying NRF2 target
genes by ChIP-seq has revealed that NRF2 directly regulates the expres-
sion of gene groups that are related to cell proliferation and survival, in
addition to the detoxification response [21]. Using ESC cell lines con-
taining NRF2 mutation, we found that mutant NRF2 promotes ESC
cell proliferation. We further revealed that mutant NRF2 confers
attachment-independent cell survival, which is intimately associated
with lymph node metastasis and tumor progression. Collectively, our
results demonstrate that aberrant NRF2 activation resulting from its
genetic alteration occurs at a relatively advanced stage of ESC and that
it induces cell proliferation and survival signals, resulting in acquisition
of malignant features and poor prognosis.
Molecular Signature of NRF2 Mutation and Chemoradiation
Therapy in ESC
In addition to these malignant characters of cancer cells, resistance
to current therapies would also be associated with a poorer survival
rate. Previous studies have shown that NRF2 activation by loss-of-
function mutations or down-regulation of the Keap1 gene confers re-
sistance to chemotherapeutic drugs and radiation [14,15,18,31]. As
has been reported in lung cancer [19], down-regulation of mutant
NRF2 enhanced the sensitivity of ESC cells to a chemotherapeutic
agent. Furthermore, mutant NRF2 regulates resistance to irradiation
partly through induction of enzymes related to glutathione synthesis.
Consequently, effective inhibition of aberrant NRF2 signaling could
offer a novel therapeutic approach for ESC in combination with CRT.
Interestingly, robust reduction of mutant NRF2 was required to inhibit
Table 4. NRF2 Target Genes Enriched in the CRT-predictive Pathways.
Pathway Gene Symbol Gene Name
ET743PT650_COLONCA_DN MGMT O6-methylguanine-DNA methyltransferase
LRBA LPS-responsive vesicle trafficking, beach, and anchor containing
KIFAP3 Kinesin-associated protein 3
IRS1 Insulin receptor substrate 1
GBE1 Glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme,
Andersen disease, glycogen storage disease type IV)
ADK Adenosine kinase
BRE Brain and reproductive organ-expressed (TNFRSF1A modulator)
UVB_NHEK3_C7 PGD Phosphogluconate dehydrogenase
ESD Esterase D/formylglutathione hydrolase
ADK Adenosine kinase
PAM Peptidylglycine alpha-amidating monooxygenase
AKR1A1 Aldo-keto reductase family 1, member A1 (aldehyde reductase)
CDKN3 Cyclin-dependent kinase inhibitor 3
(CDK2-associated dual-specificity phosphatase)
PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent)
BRCA1KO_MEF_DN PDIA4 Protein disulfide isomerase family A, member 4
GPT2 Glutamic pyruvate transaminase (alanine aminotransferase) 2
MAN1A1 Mannosidase, alpha, class 1A, member 1
LAMC1 Laminin, gamma 1 (formerly LAMB2)
ADD3 Adducin 3 (gamma)
CDC2L6 Cell division cycle 2-like 6 (CDK8-like)
KLF9 Kruppel-like factor 9
CMV_HCMV_TIMECOURSE_24HRS_DN WNT5A Wingless-type MMTV integration site family, member 5A
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1
ANXA1 Annexin A1
VEGFC Vascular endothelial growth factor C
ADD3 Adducin 3 (gamma)
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resistance to radiation and induction of glutathione-regulating en-
zymes. Combined with other analyses, it could be possible that there
are distinct groups of target genes regulated by mutant NRF2 in ESC
cells. One group is sensitive to the amount of NRF2 and includes genes
associated with cell proliferation, colony formation, and 5-FU resis-
tance. The other is relatively resistant to NRF2 reduction and is respon-
sible for attachment-independent survival and radiation resistance.
Our in vitro analyses also suggest that NRF2 activation could be
associated with a poorer response to CRT in clinical cases of ESC. To
examine this hypothesis, we carried out gene expression profiling,
in view of the difficulty in collecting sufficient samples of pre-CRT tu-
mors for mutation analysis. A number of previous studies have reported
the identification of biomarkers that are predictive of the response of
ESC to 5-FU or 5-FU–based neoadjuvant CRT [32–34]. Previously
reported molecular makers have been categorized into several groups,
including those related to 5-FU metabolism (e.g., thymidylate synthase
and thymidine phosphorylase), the DNA repair pathway (e.g., excision
repair cross-complementing rodent repair deficiency, complementation
group 1 [ERCC1] and TP53), hypoxia (hypoxia-inducible factor 1α
and vascular endothelial growth factor), and apoptosis/survival sig-
naling (e.g., survivin, Bax, epidermal growth factor receptor, and
Cox2) [32]. We tested the association between the expression level of
ERCC1 or survivin and the clinical response to CRT in our cohort,
but found no significant relationship (ERCC1, P = .209; survivin,
P = .327). In contrast to these studies focusing on molecules with func-
tional associations, only a few studies have explored microarray data
in an unbiased way to search for biomarkers predictive of CRT effi-
cacy, and only a limited number of cases (n = 13, 19, or 20) were
examined [35–37].
In the present study, we adopted a different approach because
NRF2 regulates a network of genes related to various molecular path-
ways at a different dose-response interaction. Instead of focusing on
the expression of individual genes, we carried out “pathway analysis,”
which seems to be more relevant to biologic phenotypes, including
therapeutic response [38]. Based on the gene expression data for ESC
cell lines, we extracted a number of functionally annotated pathways
whose expression was associated with the presence of NRF2 muta-
tion, which was also supported by ChIP-seq data of NRF2. We then
used microarray data for the largest pre-CTR biopsy cohort ever re-
ported (33 cases) and evaluated these pathways for predictive and
prognostic utility. In total, up-regulation of 15 pathways was found
to be significantly associated with a poor response to CRT and unfa-
vorable prognosis, and our analysis revealed that expression of the gene
sets related to oxidative stress and the immune response is associated
with the clinical response of ESC to CRT and patient prognosis.
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Table W1. Primers and Antibodies Used in This Study.
Gene Name Forward PCR Primer Reverse PCR Primer Roche Universal, No.
GCLC ggatgatgctaatgagtctgacc tctactctccatccaatgtctgag 25
GSR aacaacatcccaactgtggtc ccatatttatgaatggcttcatctt 83
GAPDH ccaaccgcgagaagatga ccagaggcgtacagggatag 64
Antibodies Used in This Study
Antigen Vendor Clone No. Dilution for Immunoblot
NRF2 Santa Cruz Polyclonal ×500
β-Actin Sigma Monoclonal AC-15 ×1000
Lamin B1 Santa Cruz Polyclonal ×500
Table W2. Pathologic Diagnosis of the Analyzed Sarcoma Cases.
Case No. Histology
028-L Leiomyosarcoma
029-L Leiomyosarcoma
032-L Leiomyosarcoma
034-L Leiomyosarcoma
035-L Leiomyosarcoma
037-L Leiomyosarcoma
038-L Leiomyosarcoma
039-L Leiomyosarcoma
040-L Leiomyosarcoma
093-mL Liposarcoma, myxoid
094-mL Liposarcoma, myxoid
095-mL Liposarcoma, myxoid
096-mL Liposarcoma, myxoid
097-mL Liposarcoma, myxoid
098-mL Liposarcoma, myxoid
099-mL Liposarcoma, myxoid
100-mL Liposarcoma, myxoid
101-mL Liposarcoma, myxoid
102-mL Liposarcoma, myxoid
103-mL Liposarcoma, myxoid
105-mL Liposarcoma, myxoid
106-mL Liposarcoma, myxoid
108-mL Liposarcoma, myxoid
020-M MPNST
022-M MPNST
023-M MPNST
024-M MPNST
025-M MPNST
026-M MPNST
056-mM Myxoid MFH
057-mM Myxoid MFH
060-mM Myxoid MFH
062-mM Myxoid MFH
063-mM Myxoid MFH
065-mM Myxoid MFH
066-mM Myxoid MFH
067-mM Myxoid MFH
068-mM Myxoid MFH
069-mM Myxoid MFH
070-mM Myxoid MFH
073-pM Pleomorphic MFH
074-pM Pleomorphic MFH
075-pM Pleomorphic MFH
077-pM Pleomorphic MFH
078-pM Pleomorphic MFH
079-pM Pleomorphic MFH
Table W2. (continued )
Case No. Histology
080-pM Pleomorphic MFH
081-pM Pleomorphic MFH
082-pM Pleomorphic MFH
083-pM Pleomorphic MFH
084-pM Pleomorphic MFH
085-pM Pleomorphic MFH
086-pM Pleomorphic MFH
087-pM Pleomorphic MFH
088-pM Pleomorphic MFH
RMS-16 Rhabdomyosarcoma
RMS-17 Rhabdomyosarcoma
RMS-18 Rhabdomyosarcoma
043-S Synovial sarcoma
044-S Synovial sarcoma
045-S Synovial sarcoma
046-S Synovial sarcoma
049-S Synovial sarcoma
051-S Synovial sarcoma
052-S Synovial sarcoma
054-S Synovial sarcoma
055-S Synovial sarcoma
SS1 Synovial sarcoma
SS11 Synovial sarcoma
SS12 Synovial sarcoma
SS13 Synovial sarcoma
SS14 Synovial sarcoma
SS2 Synovial sarcoma
SS3 Synovial sarcoma
SS4 Synovial sarcoma
SS5 Synovial sarcoma
SS6 Synovial sarcoma
SS7 Synovial sarcoma
SS8 Synovial sarcoma
SS9 Synovial sarcoma
OS-41 Osteosarcoma
OS-44 Osteosarcoma
OS-45 Osteosarcoma
OS-46 Osteosarcoma
OS-47 Osteosarcoma
OS-49 Osteosarcoma
ES-01 Epithelioid sarcoma
ES-02 Epithelioid sarcoma
ES-04 Epithelioid sarcoma
ES-05 Epithelioid sarcoma
ES-06 Epithelioid sarcoma
ES-10 Epithelioid sarcoma
Figure W1. NRF2-dependent transcriptional activity in homo-
zygous (KYSE70) and heterozygous (KYSE110) cells. n.s. indicates
not significant.
Figure W2. The expression of proliferating cell nuclear antigen
(PCNA) in control (Cont) and NRF2 (sh-1 and sh-2) shRNA expres-
sion clones. Protein extracted from each clone were immuno-
blotted with anti-PCNA mouse antibody (clone PC10; Cell Signaling
Technologies, Danvers, MA). β-Actin was used as a loading control.
Molecular marker is indicated on the right (kDa).
Figure W3. 5-FU sensitivity and basal colony formation capacity of NRF2 wild-type (KYSE220) and mutated (KYSE70, KYSE110,
KYSE180) ESC cell lines. (A) ESC cells were treated with various concentrations of 5-FU, and relative cell proliferation was shown.
(B) Number of colony formation of each ESC cell was shown.
Figure W4. KYSE70 clones were irradiated (4 Gy), and the amount
of intracellular reduced glutathione was measured after 24 hours.
